Elicio Therapeutics Faces Major Setback After Clinical Trial Failure
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 28 2026
0mins
Source: stocktwits
Elicio Therapeutics Inc. saw its stock rise by 7.01% as it crossed above the 5-day SMA, despite the overall market decline with the Nasdaq-100 down 0.62% and the S&P 500 down 0.42%.
The recent news surrounding Elicio highlights a significant setback as its ELI-002 7P failed to meet the primary disease-free survival endpoint in the AMPLIFY-7P trial. This failure has led to a severe decline in investor confidence, with the stock previously plummeting by over 72% following the announcement. Despite this, the stock's current rise may be attributed to a temporary market reaction or speculative trading, as broader market conditions remain weak.
The implications of this trial failure are profound, as it not only affects Elicio's immediate financial outlook but also raises questions about its future in the competitive biotech landscape. Investors are advised to remain cautious as the company navigates these challenges.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ELTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ELTX
Wall Street analysts forecast ELTX stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.295
Low
13.00
Averages
15.50
High
18.00
Current: 3.295
Low
13.00
Averages
15.50
High
18.00
About ELTX
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Elicio Therapeutics Under Investigation for Securities Fraud
- Stock Price Plunge: Elicio Therapeutics announced on June 15, 2026, that its Phase 2 AMPLIFY-7P study failed to meet the pre-specified primary endpoint, resulting in a staggering 70.96% drop in stock price, falling $9.97 to close at $4.08, severely undermining investor confidence.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Elicio and its executives engaged in securities fraud or other unlawful business practices, indicating potential legal risks that could lead to further financial losses and reputational damage for the company.
- Poor Clinical Trial Results: The failure of the AMPLIFY-7P study to achieve the disease-free survival endpoint in the intent-to-treat population may hinder Elicio's future financing and market competitiveness, limiting its development in the pancreatic cancer treatment space.
- Investor Advisory: Pomerantz LLP advises Elicio investors to contact their attorneys, highlighting the risk of potential class action lawsuits against the company, which exacerbates market concerns regarding its future prospects.
See More
Idaho Copper Sets Public Offering Price
- Offering Price Set: Idaho Copper has priced its underwritten public offering of stocks and warrants at $4.85 each, indicating a stable demand for its financing in the market.
- Clear Financing Purpose: The public offering aims to provide funding for the company's operations and expansion, which is expected to enhance its competitiveness in the copper market and drive future growth.
- Market Reaction Monitoring: While specific market reactions have not been disclosed, the pricing strategy reflects the company's confidence in the current market environment, potentially attracting investor interest.
- Strategic Implications: Through this financing, Idaho Copper can further invest in its mining projects, increasing production capacity to capitalize on the growing global demand for copper.
See More
Elicio Plans $15 Million Offering to Fund Clinical Development of ELI-002 7P
- Offering Announcement: Elicio Therapeutics has announced a $15 million registered direct offering expected to conclude by July 6, aimed at funding the Phase 1 clinical development of ELI-002 7P for metastatic pancreatic cancer, highlighting the urgency of its financial strategy post-clinical setbacks.
- Clinical Trial Setback: On June 15, Elicio reported that its mid-stage study of ELI-002 7P failed to meet its primary endpoint, resulting in a premarket stock plunge of over 24%, reflecting significant investor concern regarding the drug's efficacy and future prospects.
- Use of Proceeds: The company plans to utilize the proceeds from this offering, along with existing cash reserves and marketable securities, to support the clinical development of ELI-002 7P, pipeline projects, and general administrative expenses, indicating a strategic focus on maintaining operational viability.
- Bearish Market Sentiment: Despite raising approximately $13 million through its at-the-market program, retail sentiment around ELTX remains bearish, with the stock declining over 36% this year, suggesting a lack of confidence among investors following the recent clinical trial results.
See More
Elicio Therapeutics Raises $15 Million Through Share Offering
- Financing Agreement: Elicio Therapeutics has entered into a securities purchase agreement with two institutional investors and a large existing shareholder to sell 4.38 million shares, expected to raise approximately $15 million, which will primarily fund the clinical development of ELI-002 7P.
- Clinical Development Focus: The company intends to use the proceeds mainly for the Phase 1 clinical trial of ELI-002 7P targeting metastatic pancreatic ductal adenocarcinoma, while allocating some funds to its pipeline, working capital, and general corporate purposes, indicating a strong commitment to drug development.
- Financial Update: As of March 31, 2026, Elicio reported cash and cash equivalents of $14.9 million, projected to sustain operations into Q4 2026, despite a net loss widening to $11.8 million in Q1, highlighting ongoing pressures from R&D investments.
- Stock Price Fluctuations: ELTX shares have traded between $2.66 and $16 over the past year, closing at $5.14 on Wednesday with a 31.46% increase, but fell 7% to $4.78 in after-hours trading, reflecting mixed market sentiment regarding the company's financing and future prospects.
See More
Elicio Therapeutics Prices $15M Direct Offering to Fund Clinical Development
- Offering Size: Elicio Therapeutics priced approximately 4.38 million shares at about $3.43 each, raising $15 million to fund the clinical development of ELI-002 7P, particularly targeting metastatic pancreatic ductal adenocarcinoma (PDAC).
- Investor Composition: The offering is led by two new fundamental institutional investors with participation from an existing large shareholder, indicating some market confidence in Elicio despite recent clinical data setbacks.
- Use of Proceeds: The net proceeds will support the Phase 1 clinical development of ELI-002 7P, advance the broader pipeline, and provide working capital and general corporate purposes, aiming to enhance the company's financial flexibility.
- Market Reaction: Following the offering announcement, Elicio's stock price dropped about 5% during pre-market trading on Thursday, reflecting investor concerns regarding the company's future prospects, particularly after disappointing Phase 2 data for its pancreatic cancer asset.
See More
Elicio Therapeutics Secures $15 Million in Direct Offering
- Financing Agreement: Elicio Therapeutics has entered into a definitive agreement with two new institutional investors and a large existing shareholder to issue 4,380,313 shares of common stock in a registered direct offering, expected to raise approximately $15 million, thereby strengthening the company's financial position to support clinical development.
- Use of Proceeds: The net proceeds from this offering will primarily fund the Phase 1 clinical development of ELI-002 7P for metastatic pancreatic cancer, while also supporting the company's pipeline and general corporate purposes, ensuring the continuity and stability of its R&D activities.
- Market Potential Assessment: ELI-002 7P targets the most common KRAS mutations present in 25% of solid tumors, aiming to enhance immune responses and potentially provide new treatment options for high-risk patients, thereby expanding market share.
- Strategic Development Direction: Elicio plans to initiate a Phase 1 study in metastatic pancreatic cancer following funding, designed to rapidly assess clinical activity and inform future treatment strategies, demonstrating the company's ongoing innovation in personalized cancer immunotherapy.
See More
Elicio Therapeutics Under Investigation for Securities Fraud
- Stock Price Plunge: Elicio Therapeutics announced on June 15, 2026, that its Phase 2 AMPLIFY-7P study failed to meet the pre-specified primary endpoint, resulting in a staggering 70.96% drop in stock price, falling $9.97 to close at $4.08, severely undermining investor confidence.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Elicio and its executives engaged in securities fraud or other unlawful business practices, indicating potential legal risks that could lead to further financial losses and reputational damage for the company.
- Poor Clinical Trial Results: The failure of the AMPLIFY-7P study to achieve the disease-free survival endpoint in the intent-to-treat population may hinder Elicio's future financing and market competitiveness, limiting its development in the pancreatic cancer treatment space.
- Investor Advisory: Pomerantz LLP advises Elicio investors to contact their attorneys, highlighting the risk of potential class action lawsuits against the company, which exacerbates market concerns regarding its future prospects.
See More
Idaho Copper Sets Public Offering Price
- Offering Price Set: Idaho Copper has priced its underwritten public offering of stocks and warrants at $4.85 each, indicating a stable demand for its financing in the market.
- Clear Financing Purpose: The public offering aims to provide funding for the company's operations and expansion, which is expected to enhance its competitiveness in the copper market and drive future growth.
- Market Reaction Monitoring: While specific market reactions have not been disclosed, the pricing strategy reflects the company's confidence in the current market environment, potentially attracting investor interest.
- Strategic Implications: Through this financing, Idaho Copper can further invest in its mining projects, increasing production capacity to capitalize on the growing global demand for copper.
See More
Elicio Plans $15 Million Offering to Fund Clinical Development of ELI-002 7P
- Offering Announcement: Elicio Therapeutics has announced a $15 million registered direct offering expected to conclude by July 6, aimed at funding the Phase 1 clinical development of ELI-002 7P for metastatic pancreatic cancer, highlighting the urgency of its financial strategy post-clinical setbacks.
- Clinical Trial Setback: On June 15, Elicio reported that its mid-stage study of ELI-002 7P failed to meet its primary endpoint, resulting in a premarket stock plunge of over 24%, reflecting significant investor concern regarding the drug's efficacy and future prospects.
- Use of Proceeds: The company plans to utilize the proceeds from this offering, along with existing cash reserves and marketable securities, to support the clinical development of ELI-002 7P, pipeline projects, and general administrative expenses, indicating a strategic focus on maintaining operational viability.
- Bearish Market Sentiment: Despite raising approximately $13 million through its at-the-market program, retail sentiment around ELTX remains bearish, with the stock declining over 36% this year, suggesting a lack of confidence among investors following the recent clinical trial results.
See More
Elicio Therapeutics Raises $15 Million Through Share Offering
- Financing Agreement: Elicio Therapeutics has entered into a securities purchase agreement with two institutional investors and a large existing shareholder to sell 4.38 million shares, expected to raise approximately $15 million, which will primarily fund the clinical development of ELI-002 7P.
- Clinical Development Focus: The company intends to use the proceeds mainly for the Phase 1 clinical trial of ELI-002 7P targeting metastatic pancreatic ductal adenocarcinoma, while allocating some funds to its pipeline, working capital, and general corporate purposes, indicating a strong commitment to drug development.
- Financial Update: As of March 31, 2026, Elicio reported cash and cash equivalents of $14.9 million, projected to sustain operations into Q4 2026, despite a net loss widening to $11.8 million in Q1, highlighting ongoing pressures from R&D investments.
- Stock Price Fluctuations: ELTX shares have traded between $2.66 and $16 over the past year, closing at $5.14 on Wednesday with a 31.46% increase, but fell 7% to $4.78 in after-hours trading, reflecting mixed market sentiment regarding the company's financing and future prospects.
See More
Elicio Therapeutics Prices $15M Direct Offering to Fund Clinical Development
- Offering Size: Elicio Therapeutics priced approximately 4.38 million shares at about $3.43 each, raising $15 million to fund the clinical development of ELI-002 7P, particularly targeting metastatic pancreatic ductal adenocarcinoma (PDAC).
- Investor Composition: The offering is led by two new fundamental institutional investors with participation from an existing large shareholder, indicating some market confidence in Elicio despite recent clinical data setbacks.
- Use of Proceeds: The net proceeds will support the Phase 1 clinical development of ELI-002 7P, advance the broader pipeline, and provide working capital and general corporate purposes, aiming to enhance the company's financial flexibility.
- Market Reaction: Following the offering announcement, Elicio's stock price dropped about 5% during pre-market trading on Thursday, reflecting investor concerns regarding the company's future prospects, particularly after disappointing Phase 2 data for its pancreatic cancer asset.
See More
Elicio Therapeutics Secures $15 Million in Direct Offering
- Financing Agreement: Elicio Therapeutics has entered into a definitive agreement with two new institutional investors and a large existing shareholder to issue 4,380,313 shares of common stock in a registered direct offering, expected to raise approximately $15 million, thereby strengthening the company's financial position to support clinical development.
- Use of Proceeds: The net proceeds from this offering will primarily fund the Phase 1 clinical development of ELI-002 7P for metastatic pancreatic cancer, while also supporting the company's pipeline and general corporate purposes, ensuring the continuity and stability of its R&D activities.
- Market Potential Assessment: ELI-002 7P targets the most common KRAS mutations present in 25% of solid tumors, aiming to enhance immune responses and potentially provide new treatment options for high-risk patients, thereby expanding market share.
- Strategic Development Direction: Elicio plans to initiate a Phase 1 study in metastatic pancreatic cancer following funding, designed to rapidly assess clinical activity and inform future treatment strategies, demonstrating the company's ongoing innovation in personalized cancer immunotherapy.
See More
